Oestrogen and the sexual dimorphism of pulmonary arterial hypertension: A translational challenge

European Respiratory Journal

Volumn 41, Issue 5, 2013, Pages 1014-1016

  Paulus, Jessica K ^a,b   Roberts, Kari E ^c  

^a TUFTS UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN;

AGE; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; HUMAN; LUNG BLOOD FLOW; LUNG CIRCULATION; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RISK FACTOR; SEX DIFFERENCE; SEX HORMONE DETERMINATION; SIGNAL TRANSDUCTION;

ANIMALS; ENDOTHELIN-1; EPOPROSTENOL; ESTRADIOL; FEMALE; HYPERTENSION, PULMONARY; NITRIC OXIDE;

EID: 84877089029     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00021713     Document Type: Editorial

References (36)

1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-223. (Pubitemid 17137857)
2. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
3. Badesch DB, Raskob GE, Elliot CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376-387.
4. Zhang R, Dai LZ, Xie WP, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest 2011; 140: 301-309.
5. Ling Y, Johnson MK, Kiely DG, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United kingdom and Ireland. Am J Respir Crit Care Med 2012; 186: 790-796.
6. Escribano-Subias P, Blanco I, López-Mesequer M, et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J 2012; 40: 596-603.
7. Vassalle C, Simoncini T, Chedraui P, et al. Why sex matters: the biological mechanisms of cardiovascular disease. Gynecol Endocrinol 2012; 28: 746-751.
8. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-1811. (Pubitemid 29266405)
9. Lahm T, Albrecht M, Fisher AJ, et al. 17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. Am J Respir Crit Care Med 2012; 185: 965-980.
10. White K, Dempsie Y, Nilsen M, et al. The serotonin transporter, gender, and 17β oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res 2011; 90: 373-382.
11. Yuan P, Wu WH, Gao L, et al. Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, prostaglandin and endothelin-1 pathways. Eur Respir J 2013; 41: 1116-1125.
12. Tofovic SP, Zhang X, Zhu H, et al. 2-Ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling. Vascul Pharmacol 2008; 48: 174-183.
13. Nishida M, Hasegawa Y, Tanida I, et al. Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats. Eur J Pharmacol 2009; 614: 70-76.
14. Umar S, Iorga A, Matori H, et al. Estrogen rescues preexisting severe pulmonary hypertension in rats. Am J Respir Crit Care Med 2011; 184: 715-723.
15. Umar S, Rabinovitch M, Eghbali M. Estrogen paradox in pulmonary hypertension: current controversies and future perspectives. Am J Respir Crit Care Med 2012; 186: 125-131.
16. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
17. Sweeney L, Voelkel NF. Estrogen exposure, obesity and thyroid disease in women with severe pulmonary hypertension. Eur J Med Res 2009; 14: 433-442.
18. Jaïs X, Olsson KM, Barbera JA, et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J 2012; 40: 881-885.
19. Duarte AG, Thomas S, Safdar Z, et al. Management of pulmonary arterial hypertension during pregnancy: a retrospective, multicenter experience. Chest 2013 [in press DOI: 10.1378/chest.12-0528].
20. Katsuragi S, Yamanaka K, Neki R, et al. Maternal outcome in pregnancy complicated with pulmonary arterial hypertension. Circ J 2012; 76: 2249-2254.
21. Scorza R, Caronni M, Bazzi S, et al. Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci 2002; 966: 238-246. (Pubitemid 34729180)
22. Beretta L, Caronni M, Origgi L, et al. Hormone replacement therapy may prevent the development of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Scand J Rheumatol 2006; 35: 468-471.
23. Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.
24. Lee WT, Ling Y, Sheares KK, et al. Predicting survival in pulmonary arterial hypertension in the UK. Eur Respir J 2012; 40: 604-611.
25. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
26. Ventetuolo CE, Ouyang P, Bluemka DA, et al. Sex hormones are associated with right ventricular structure and function: the MESA-right ventricle study. Am J Respir Crit Care Med 2011; 183: 659-667.
27. Gabler NB, French B, Strom BL, et al. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 2012; 141: 20-26.
28. Machado RD, Eickelberg O, Elliot CG, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S32-S42.
29. Austin ED, Hamid R, Hemnes AR, et al. BMPR2 expression is suppressed by signaling through the estrogen receptor. Biol Sex Differ 2012; 3: 6.
30. Austin ED, Cogan JD, West JD, et al. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J 2009; 34: 1093-1099.
31. Roberts KE, Fallon MB, Krowka MJ, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 2009; 179: 835-842.
32. McLaughlin VV, Suissa S. Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare diseases. Circulation 2010; 122: 106-108.
33. Wacholder S, McLaughlin JK, Silverman DT, et al. Selection of controls in case-control studies. I. Principles. Am J Epidemiol 1992; 135: 1019-1028.
34. Helzlsouer KJ, VDPP Steering Committee. Overview of the cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol 2010; 172: 4-9.
35. Hörig H, Marincola E, Marincola FM. Obstacles and opportunities in translational research. Nat Med 2005; 11: 705-708. (Pubitemid 41021194)
36. Khoury MJ, Gwinn M, Ioannidis JP. The emergence of translational epidemiology: from scientific discovery to population health impact. Am J Epidemiol 2010; 172: 517-524.